Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A clinical study of NI007 for the treatment of COVID-19

Trial Profile

A clinical study of NI007 for the treatment of COVID-19

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 07 Apr 2020

At a glance

  • Drugs NI 007 (Primary)
  • Indications COVID 2019 infections
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Apr 2020 New trial record
    • 31 Mar 2020 According to a Neurimmune Therapeutics media release, the company expects to begin clinical testing in the fourth quarter of 2020, pending regulatory approval.

Trial Overview

Purpose

This study will evaluate NI 007.

Diseases Treated

Indication Qualifiers Patient Segments
COVID 2019 infections treatment -

Subjects

  • Subject Type patients
  • Sex male & female

Trial Details

Organisations

  • Affiliations Neurimmune Therapeutics

Trial Dates

  • Initiation Dates

    Planned : 01 Oct 2020

Other Details

  • Design prospective
  • Phase of Trial Phase I
  • Location Unknown
  • Focus Adverse reactions

Interventions

Drugs Route Formulation
NI 007Primary Drug Inhalation
-

Trial History

Event Date Event Type Comment
07 Apr 2020 New trial record New trial record Updated 07 Apr 2020
31 Mar 2020 Other trial event According to a Neurimmune Therapeutics media release, the company expects to begin clinical testing in the fourth quarter of 2020, pending regulatory approval. Updated 07 Apr 2020

References

  1. Neurimmune Therapeutics, Ethris. Neurimmune and Ethris Sign Collaboration Agreement to Rapidly Develop Inhaled mRNA-based Antibody Therapy for the Treatment of COVID-19. Media-Rel 2020;.

    Media Release
Back to top